Forma Therapeutics Holdings

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q3 2021 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021

Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting

Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced positive initial results from a Phase 1 trial of its novel CBP/p300 inhibitor, the oral small molecule FT-7051, in men with metastatic castration-resistant prostate cancer (mCRPC). Initial clinical data from the Courage Study, an ongoing first-in-human Phase

Forma Therapeutics' FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Participate in Upcoming Investor Conferences.

Forma Therapeutics to Participate in Upcoming Investor Conferences

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q2 2021 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021

Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer

Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D.

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease. Data were presented at the Annual European Hematology Association (EHA) 2021 Virtual Congress.

Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced new data from its ongoing Phase 1 trial of etavopivat (formerly referred to as FT-4202) being presented at the 26th Annual European Hematology Association (EHA) 2021 Virtual Congress. The e-poster presentation includes initial data from the open-label extension (OLE) cohort showing etavopivat improved and

Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q1 2021 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021

Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q4 2020 Results - Earnings Call Transcript

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator. The 600 mg high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but FT-4202 showed a similar safety and tolerability profile as the 300 mg cohort, despite the doubling of the dose.

Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results from Q4 and full year 2020, as well as business updates.

Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive data from the 600 mg cohort in the Phase 1 trial of FT-4202 in sickle cell patients.

Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that the company will release fourth quarter and year-end 2020 financial results on Tuesday, March 30, 2021.

Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021

Forma Therapeutics (FMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Forma Therapeutics (FMTX) Might Surprise This Earnings Season

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the first patient dosed in Phase 1 clinical trial evaluating FT-7051 in metastatic castration-resistant prostate cancer.

Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics provides a review of 2020 company highlights and an outline of anticipated 2021 milestones.

Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that renowned doctor Selwyn M. Vickers, M.D., has been elected to the company's board of directors.

News for Forma Therapeutics Holdings Stock (FMTX)